comparemela.com
Home
Live Updates
Siendo Trial - Breaking News
Pages:
Latest Breaking News On - Siendo trial - Page 1 : comparemela.com
Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer
Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.
United states
Miami beach
Nuvation bio
Genentech incyte
Selinexor xpovio
Brian slomovitz
Gynecologic oncology at mount sinai medical center
Plenary series
Gynecologic oncology
Mount sinai medical center
Myriad genetics
Onconova therapeutics
Patients with tp53 wild type advanced or recurrent endometrial cancer
Siendo trial
Dr Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer
Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.
Darior roque
Pembrolizumab keytruda
Northwestern university feinberg school of medicine
Roberth lurie comprehensive cancer center
Gynecologic oncology
Northwestern university
Feinberg school
Comprehensive cancer center
Northwestern medicine
Advanced endometrial cancer
Siendo trial
Mismatch repair deficient
Biomarker testing
Molecular subtypes
Immune checkpoint inhibitors
Dostarlimab gxly
vimarsana © 2020. All Rights Reserved.